Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by US Bancorp DE

US Bancorp DE decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 9.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,626 shares of the biotechnology company’s stock after selling 4,484 shares during the quarter. US Bancorp DE’s holdings in Exelixis were worth $1,453,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FMR LLC increased its stake in shares of Exelixis by 6.1% in the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after purchasing an additional 140,568 shares during the period. Los Angeles Capital Management LLC boosted its holdings in shares of Exelixis by 20.4% in the fourth quarter. Los Angeles Capital Management LLC now owns 2,156,996 shares of the biotechnology company’s stock valued at $71,828,000 after acquiring an additional 366,141 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in Exelixis by 6.1% during the third quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock worth $44,182,000 after buying an additional 98,000 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after buying an additional 704,786 shares in the last quarter. Finally, Systematic Financial Management LP boosted its holdings in Exelixis by 7.1% during the third quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock worth $30,320,000 after buying an additional 77,599 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $38.58 on Friday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $39.30. The company has a 50 day moving average of $34.99 and a 200-day moving average of $32.08. The stock has a market cap of $10.80 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on EXEL. Stephens restated an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 target price for the company. in a research report on Monday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, February 13th. Finally, Brookline Capital Management initiated coverage on shares of Exelixis in a report on Monday, December 23rd. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $37.24.

Insider Transactions at Exelixis

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the firm’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the transaction, the director now owns 356,605 shares of the company’s stock, valued at approximately $13,479,669. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares of the company’s stock, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 140,343 shares of company stock valued at $5,177,234 over the last quarter. Corporate insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.